Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine

Table 2 Factors associated with completion of therapy

	Not Completed		Completed		Unadjusted			Adjusted
	n	percent	n	percent	RR	95% CI	p-value	RR	95% CI	p-value
Type of Therapy^a,b
Isoniziad + Rifpaentine	13	14.9	74	85.1	Reference			Reference
Rifampin only	12	14.6	70	85.4	1.00	0.88, 1.14	0.96	0.88	0.55, 1.38	0.57
Isoniazid only	107	48.2	115	51.8	0.61	0.52, 0.71	<0.001	0.58	0.36, 0.93	0.02
Isoniazid only (vs rifampin only)					0.61	0.52, 0.71	<0.001	0.66	0.56, 0.79	<0.001
Clinic^b,c
Public Health	59	22.5	203	77.5	Reference			Reference
Employee Health	20	74.1	7	25.9	0.33	0.18, 0.64	<0.001	0.37	0.20, 0.69	<0.01
International	37	54.4	31	45.6	0.59	0.45, 0.77	<0.001	0.64	0.47, 0.85	<0.01
Homeless	9	52.9	8	47.1	0.61	0.37, 1.01	0.06	0.65	0.38, 1.09	0.10
Infectious Diseases	7	41.2	10	58.8	0.76	0.51, 1.14	0.18	0.74	0.48, 1.12	0.16
Type of monitoring^a,c
Weekly DOT/phone calls	13	15.1	73	84.9	Reference			Reference
Monthly clinic visits	38	27.3	101	72.7	0.86	0.75, 0.98	0.03	1.12	0.71, 1.76	0.62
Less often	81	48.8	85	51.2	0.60	0.51, 0.72	<0.001	1.21	0.75, 1.96	0.43
Side effects^c	37	28.2	94	71.8	1.13	0.98, 1.30	0.09	1.03	0.90, 1.18	0.66
Number of other medical problems^a,d
0	47	26.6	130	73.5	Reference			Reference
1-2	42	35.3	77	64.7	0.88	0.75, 1.03	0.12	1.00	0.84, 1.19	1.00
3+	43	45.3	52	54.7	0.75	0.61, 0.91	0.01	1.08	0.88, 1.33	0.47

ISSN: 1471-2334